是时候考虑药物治疗未破裂的内动脉瘤了吗?
Yeon Soo Kim1,2, Sungbin Hwang1,2, Mi Hyeon Kim1,2
1Biomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Seoul, Korea.
Journal of stroke
|September 16, 2025
概括
药物治疗可能为管理未破裂的内动脉瘤 (UIAs) 提供一种新的方法,可能减少生长和破裂风险. 需要进一步的研究,以制定标准化的治疗指南,以应对这种情况.
科学领域:
- 神经学 神经学
- 血管外科 血管外科
- 药理学 药理学是指药理学的学科.
背景情况:
- 越来越多地检测到未破裂的内动脉瘤 (UIA),需要除了侵入性手术之外的其他治疗方法.
- 目前对UIA进行的手术和内血管干预具有风险,高成本和心理负担.
- 先进的成像突出了对不那么侵入性UIA管理策略的需求.
研究的目的:
- 探索药理疗法在治疗UIA中的潜在作用.
- 审查驱动UIA进展和不稳定的病理生理机制.
- 检查UIA治疗中各种药理学药物的现有证据.
主要方法:
- 对UIA生长的关键病理生理机制的审查:内皮功能障碍,血液动力学压力,炎症和血栓形成.
- 对药理学药物 (抗高血压药物,降脂药物,抗炎药物,抗氧化剂,新候选药物) 的临床前和观察证据的检查.
- 综合当前的临床数据和识别知识差距.
主要成果:
- 临床前和观察数据表明,各种药理学剂在缓解UIA进展方面具有潜在的益处.
- 关键的病理生理路径为向药物治疗提供了理由.
- 目前的临床证据不足以支持UIA的标准化药理治疗指南.
结论:
- 药理干预措施对UIA管理有希望,补充现有策略.
- 进一步的前性和随机研究对于确定这些药物的安全性和有效性至关重要.
- 结合药物,生活方式变化和监测的综合方法对于最佳的UIA患者护理至关重要.
相关概念视频
01:26Aneurysm III: Interprofessional Care
255
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
255
01:22Aneurysm IV: Nursing Management
391
Vigilant monitoring for aneurysm rupture is essential for patients undergoing aortic surgery.Preoperative Nursing ManagementContinuously monitor the patient for manifestations of aneurysm rupture, such as pallor, weakness, tachycardia, hypotension, abdominal, back, groin, or periumbilical pain, changes in consciousness, and a pulsating abdominal mass. Regularly assess the patient's peripheral pulses.Instruct the patient to consume a clear liquid diet the day before surgery and administer...
391
01:25Aortic Regurgitation III: Medical Management
399
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
399
01:26Angina IV: Management
238
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
238
01:27Peripheral Artery Disease III: Interprofessional Care
248
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
248
01:26Atherosclerosis III: Management
322
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
322